Phase 3 Chronic Rhinosinusitis Trial, Not Yet Recruiting NCT06740045 Sponsor: Dr. Andrew Thamboo, MD Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Phase 3 Chronic Rhinosinusitis Trial, Not Yet Recruiting

NCT06740045
Not Yet Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 19 years of age or older when you sign the consent form
  • You must be able to understand and sign a consent form agreeing to take part
  • You must have been diagnosed with chronic sinusitis with nasal polyps, based on symptoms and/or scans or camera examinations of your nose and sinuses
  • You must have severe asthma, confirmed through breathing tests
  • You must have nasal polyps of a certain size — at least a score of 2 on each side of your nose (confirm with trial site)
  • If you are a woman who could become pregnant, you must agree to use an acceptable form of birth control during the study and have a negative pregnancy test at each visit
  • You must not be planning to have surgery within the next 7 months

Who may not be able to join:

  • You have previously had sinus surgery or surgery to remove nasal polyps
  • You have a history of organ transplantation, such as a lung transplant
  • You have previously used or are currently using medications that affect the immune system, or antihistamines (allergy medications)
  • You have a history of autoimmune diseases (conditions where the body attacks itself)
  • You have had or currently have any tumours in your sinuses, nose, or airways
  • You are currently taking steroid tablets or steroid medications taken by mouth
  • You are pregnant, planning to become pregnant, or are breastfeeding during the trial
  • You are currently taking part in another clinical trial involving a treatment
  • The trial doctors feel you are unlikely to attend study visits as required
  • You have been diagnosed with, or are suspected of having, a serious nasal condition such as certain types of nasal growths or polyps on only one side of the nose
  • You have a fungal sinus infection or have tested positive for a specific mould called Aspergillus
  • You have had cancer within the last 5 years (some skin cancers treated locally and one type of cervical condition may be exceptions — confirm with trial site)
  • You have a bleeding disorder or cannot safely stop blood-thinning medications for a nasal tissue sample (biopsy)
  • You have a severe nasal deformity that would prevent a camera examination inside your nose
  • You are currently being treated for a long-term infection such as certain viral, fungal, or bacterial infections
  • You have been hospitalised for a serious infection requiring intravenous or injected antibiotics within the last 60 days
  • You have been treated as an outpatient with intravenous or injected antibiotics for a serious infection within the last 60 days
  • You have a known positive HIV diagnosis
  • You have a known positive Hepatitis B or Hepatitis C diagnosis
  • You have a significant unstable or poorly controlled long-term illness that the trial doctor feels could affect the results or put you at risk
  • You have a planned surgery, unusual test result, or other condition that the trial doctor feels makes you unsuitable
  • You have received an experimental medication (not approved for sale in Canada) within the last 60 days
  • You are a current or past smoker with a heavy smoking history of more than 15 pack-years (confirm with trial site on how this is calculated)
  • You have a current parasitic (worm-related) infection
  • You have a known allergy or intolerance to a type of medication called a monoclonal antibody or biologic therapy
  • You are allergic to Aspirin or anti-inflammatory pain medications (such as ibuprofen)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Andrew Thamboo, St Paul's Sonis Centre Director

Phone: 604-250-4174

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 3
Sponsor
Dr. Andrew Thamboo, MD
Registry
ClinicalTrials.gov
Start date
1 January 2025
Est. completion
1 March 2025

Primary endpoints

Eosinophil Count; Neutrophil count; Basement Membrane Thickness; Fibrosis; Squamous Metaplasia; Lymphocytic Proliferation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov